Antagonism of Nerve Growth Factor-TrkA Signaling and the Relief of Pain

Author:

Mantyh Patrick W.1,Koltzenburg Martin2,Mendell Lorne M.3,Tive Leslie4,Shelton David L.5,Warner David S.

Affiliation:

1. Professor, Department of Pharmacology, University of Arizona, Tucson, Arizona, and Veterans Affairs Medical Center, Minneapolis, Minnesota.

2. Professor, University College London Institute of Neurology, Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, London, United Kingdom.

3. Distinguished Professor, Department of Neurobiology and Behavior, State University of New York at Stony Brook, Stony Brook, New York.

4. Senior Director, Pfizer Inc, New York, New York.

5. Senior Director, Rinat Laboratories, Pfizer Inc, South San Francisco, California.

Abstract

Nerve growth factor (NGF) was originally discovered as a neurotrophic factor essential for the survival of sensory and sympathetic neurons during development. However, in the adult NGF has been found to play an important role in nociceptor sensitization after tissue injury. The authors outline mechanisms by which NGF activation of its cognate receptor, tropomyosin-related kinase A receptor, regulates a host of ion channels, receptors, and signaling molecules to enhance acute and chronic pain. The authors also document that peripherally restricted antagonism of NGF-tropomyosin-related kinase A receptor signaling is effective for controlling human pain while appearing to maintain normal nociceptor function. Understanding whether there are any unexpected adverse events and how humans may change their behavior and use of the injured/degenerating tissue after significant pain relief without sedation will be required to fully appreciate the patient populations that may benefit from these therapies targeting NGF.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine

Reference151 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3